TABLE 2.
Proportion of patients who received genomically matched therapies by drug and therapy type
| Core hospital | 1st Period | 2nd Period | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All | Clinical trials | Off‐label use | Approved drugs | All | Clinical trials | Off‐label use | Approved drugs | |||
| Investigational drugs | NCCH1901 | Investigational drugs | NCCH1901 | |||||||
| A | 75 | 3 (4.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 138 | 1 (0.7%) | 7 (5.1%) | 2 (1.4%) | 8 (5.8%) |
| B | 73 | 2 (2.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 201 | 1 (0.5%) | 3 (1.5%) | 0 (0.0%) | 8 (4.0%) |
| C | 5 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 102 | 1 (1.0%) | 1 (1.0%) | 1 (1.0%) | 0 (0.0%) |
| D | 41 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 158 | 1 (0.6%) | 0 (0.0%) | 0 (0.0%) | 5 (3.2%) |
| E | 160 | 7 (4.4%) | 0 (0.0%) | 2 (1.3%) | 7 (4.4%) | 251 | 9 (3.6%) | 9 (3.6%) | 1 (0.4%) | 4 (1.6%) |
| F | 172 | 2 (1.2%) | 0 (0.0%) | 1 (0.6%) | 1 (0.6%) | 450 | 28 (6.2%) | 4 (0.9%) | 7 (1.6%) | 8 (1.8%) |
| G | 13 | 1 (7.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 83 | 0 (0.0%) | 7 (8.4%) | 0 (0.0%) | 2 (2.4%) |
| H | 85 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 218 | 2 (0.9%) | 7 (3.2%) | 1 (0.5%) | 5 (2.3%) |
| I | 13 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 142 | 6 (4.2%) | 4 (2.8%) | 4 (2.8%) | 2 (1.4%) |
| J | 24 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 221 | 1 (0.5%) | 1 (0.5%) | 1 (0.5%) | 3 (1.4%) |
| K | 93 | 1 (1.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 179 | 0 (0.0%) | 4 (2.2%) | 0 (0.0%) | 5 (2.8%) |
| L | ‐ | ‐ (‐) | ‐ (0.0%) | ‐ (‐) | ‐ (‐) | 151 | 10 (6.6%) | 0 (0.0%) | 0 (0.0%) | 2 (1.3%) |
| Total | 754 | 16 (2.1%) | 0 (0.0%) | 3 (0.4%) | 8 (1.1%) | 2294 | 60 (2.6%) | 47 (2.0%) | 17 (0.7%) | 52 (2.3%) |